Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?
A new cell therapy approach has, in low-key fashion, attracted financing and the attention of big biopharma.
Immunocore and Adaptimmune could shortly have a publicly listed rival.
The next generation of CAR-T therapies is already emerging.